|
|
Article: Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of $3.00 and Buy Rating; Analyst Cites Recent Callisto Announcement of Encouraging Anti-Tumor Response of Drug Candidate Atiprimod.
- Article from:
- Business Wire
- Article date:
- March 13, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today that General Research GmbH, a fee-based equity analysis firm based in Munich, Germany, has issued an updated report revising its 6-month share price target upward to $3.00, and reiterated its speculative 'Buy' rating.
The research firm's new target price projection represents a significant increase over previous projections that were initially issued as part of a comprehensive research report three months ago. The new target in part reflects Callisto's recent announcement of clinical ...